Last updated 2026-08-22
- Raised $8M Series D led by Guangzhou-Israel Biotechnology Fund (GIBF), Jun 2026
- Raised $15M Series C led by Deep Insight, Nov 2021
- Raised $17M Series B led by Israel Biotech Fund, Jan 2019
Total raised
$40.0M
Last: Undisclosed Round 2026-06
Stage
Series C
Founded
2016
Headcount
36
HQ
Misgav, Israel
Sector
Biotechnology
About
Biond Biologics is an Israeli clinical-stage biopharmaceutical company focused on developing breakthrough immunotherapies and a pioneering intracellular drug delivery platform for cancer treatment. The company's approach involves targeting novel immune evasion mechanisms and utilizing its INspire platform for intracellular delivery of biologics. Biond aims to translate high-quality science into transformative drugs for diseases with high unmet needs. Their pipeline includes clinical-stage oncology programs and a portfolio of discovery and preclinical programs in immune-mediated diseases.
Funding history · 3 rounds · $40.0M total
3 events/rounds · $40.0M Total Funding: $40.0M in Private Equity
Jun 2026
★ Guangzhou-Israel Biotechnology Fund (GIBF)
Nov 2021
Jan 2019
Headcount over time
36 employees (2026-09) · 1 point
Offices
Misgav, Israel · HQ / main office
Q&A
- What is Biond Biologics' primary focus?
- Biond Biologics is a biotechnology company focused on developing immunotherapies for cancer and auto-immune diseases, as well as an intracellular drug delivery platform.
- When was Biond Biologics founded?
- Biond Biologics was founded in April 2016.
- How many employees does Biond Biologics have?
- Biond Biologics has 11-50 employees.
- What is the total amount of funding Biond Biologics has raised to date?
- Biond Biologics has raised a total of $45,000,000 USD across multiple funding rounds.
- When did Biond Biologics complete its Series B funding round and who were the lead investors?
- Biond Biologics completed its Series B funding round in January 2019, with Harel Insurance & Finance as a lead investor.
- Which investors participated in Biond Biologics' Series C funding round?
- Biond Biologics' Series C funding round in November 2021 was led by Deep Insight and also included.
- Who are the co-founders of Biond Biologics?
- The co-founders of Biond Biologics are Tehila Ben Moshe, who serves as Chairperson & CEO, and Ori Shilo, who is the CFO.
Team · 14
Tehila Ben Moshe
Founder · Co-Founder, Chairperson & Chief Executive Officer
Ori Shilo
Founder · Co-Founder & Chief Financial Officer
Yair Sapir
Chief Operations Officer
Ilana Mandel
Chief Scientific Officer
Giovanni Selvaggi
Chief Medical Officer
Motti Hakim
VP R&D
Sharon Hashmueli
VP Regulatory Affairs & CMC
Tal Sines
VP Business Development
Nir Brav
VP Finance
Natalia Ashtamker
VP of Clinical Development
Ronit Bendori
Board Member
Yuval Cabilly
Board Member
Tomer Goldberg
Board Member
Barak Ben-Eliezer
Board Member
Sectors & technology
Primary sector
Biotechnology
Technologies
Target customers
Business model
B2BLicensing agreementsPartnerships
Highlights
1 PatentsVerified
Tags
pharmaceuticalsimmunologydrug-discoveryoncologyautoimmune-diseasesbiopharmaceuticalcancerpharma-companiesimmunotherapy
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | biondbio.com |
|---|---|
| linkedin.com/company/18156602 |
Identifiers & details
| Legal name | Biond Biologics Ltd. |
|---|---|
| Founded | 2016 |
| Employees (exact) | 36 |
Radar intelligence
Patents
| EPO | 18 |
|---|
Web history (Wayback)
| Domain | biondbio.com |
|---|
Certificate / subdomain footprint
| Subdomains | 4 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515445823 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2016-04-21 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 8 — people (1), shares_capital (2), annual_report (5) |
| Registered address | 4 משגב |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-28 | עדכון בעלי תפקידים |
| 2025-12-22 | הקצאת מניות |
| 2025-09-07 | דו~ח שנתי-הקצאת מניות |
| 2025-09-07 | דו~ח שנתי-שינוי בהוראות בתקנון |
| 2025-09-07 | דו~ח שנתי-עדכון תחום עיסוק |
| 2025-09-07 | דו~ח שנתי-הוספת דירקטור |
| 2025-09-07 | דו~ח שנתי-הוספת בעל תפקיד |
| 2026-07-06 | שינוי בהרכב הון - מניות-פיצול מניה |